Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to... see more

TSXV:SBM - Post Discussion

Sirona Biochem Corp > @PRC - Potential TFC-1067 - year 1-5
View:
Post by 24minus7 on Jun 26, 2022 4:24am

@PRC - Potential TFC-1067 - year 1-5

https://1drv.ms/x/s!AvRAHt7sXjA7g64TCBfGQtgwM0Humg?e=5P3cq1

Figures from year 4 onwards suggest that AbbVie/Allergan have not only been able to serve an existing market, but have also been able to create a new NEED after a high quality and high priced treatment method (skinlightening/dyschromia).

@PRC - I look forward to seeing your numbers next Monday.
Comment by navajojoe on Jun 26, 2022 11:27am
This post has been removed in accordance with Community Policy
Comment by Engcan77 on Jun 26, 2022 12:50pm
Once Sirona agrees on a contract, it is out of their hands. They are relying on the company involved to produce various products, and push for sales. Obviously so far R+F has done diddly squat for Sirona. It will take more than one product with R+F to make it worthwhile. Even then the payout to Sirona is minuscule. Upfront payment of new products...then depends on how much TFC-1067 is used in the ...more  
Comment by Pareto8020 on Jun 26, 2022 1:07pm
That's why the Allergan deal details matter and need to be released to unlock SBM's value. If the upfront isn't very large then there won't be any pressure on Allergan to get to market quickly to start making a return on their investment.  Details matter to the investment community.  I get the impression it is a fairly substantial deal given all the promised upcoming ...more  
Comment by Engcan77 on Jun 26, 2022 2:17pm
Pareto. What you just commented, was exactly what i thought also, but didn't want to ramble on.lol The upfront payment is important, because a few million upfront is more of an insentive to produce products, than pocket money of 50 grand from R+F. Supposedly Allargan spend quite a bit of cash to do their own testing on TFC-1067. That is a good sign also. 
Comment by MirrorWorldMan on Jun 26, 2022 9:24pm
Why invest money in uncertainty. History has proven Howies rhetoric to be without substance and thats all we have to go by. Repeating the displeasure doesn't change his behaviour, ER doctors cannot be CEO's. I remember in 2014 when Howie was so happy to announce he made 200 grams of 1067 as a sample. It took 8 years to announce a possibility significant deal. Now he announced he made some ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities